Skip to main content

Roche, BioPorto Ink Distribution Deal for Acute Kidney Injury Test

NEW YORK (GenomeWeb) – Danish in vitro diagnostics firm BioPorto announced today a deal with Roche for the global distribution of a neutrophil gelatinase-associated lipocalin (NGAL) test for use on the Cobas c 501 and Cobas c 502 analyzers.

NGAL is a diagnostic biomarker which can alert clinicians to acute kidney injury within a few hours, compared to the 24 to 72 hours with existing methods such as serum creatinine determination. BioPorto's NGAL Test is CE marked, and the company is currently conducting clinical studies to generate data ahead of potential approval by the US Food and Drug Administration, it said, adding approval is expected to happen later this year.

Today's deal, whose terms were not disclosed, is anticipated to begin generating revenues in 2019, BioPorto said.